RelA had been used as an evaluator to evaluate the role of NF-κB activation in various tumors, including lung adenocarcinoma (He T. et al., 2020), breast cancer (Li et al., 2020), liver cancer (Moles et al., 2016), CRC (Liu et al., 2018b; Xu et al., 2019; Wang S. et al., 2020), and so on. The gene discussed is NFKB1; the disease is breast carcinoma.